276 related articles for article (PubMed ID: 29812961)
1. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
2. Off-Label Therapeutic Potential of Crisaborole.
Makins C; Sanghera R; Grewal PS
J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
[TBL] [Abstract][Full Text] [Related]
3. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
5. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
6. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
9. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
10. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
11. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian R; Weinberg JM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1236-42. PubMed ID: 19876791
[TBL] [Abstract][Full Text] [Related]
12. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
14. Topical Crisaborole-A Potential Treatment for Recalcitrant Palmoplantar Psoriasis.
Robbins AB; Gor A; Bui MR
JAMA Dermatol; 2018 Sep; 154(9):1096-1097. PubMed ID: 30090935
[No Abstract] [Full Text] [Related]
15. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
16. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
18. Evaluating crisaborole as a treatment option for atopic dermatitis.
Ramachandran V; Cline A; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
[TBL] [Abstract][Full Text] [Related]
19. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
